February 1, 2023

mRNA Vaccines in Livestock plus Companion Animals Are Right here Now

The current (public) receipts are included in this essay, and much more are on the way

Before we can discus mRNA vaccines intended for livestock, pets and wildlife, we must first address the elephant in the room. That is, how come the public is able to entry human clinical trial information, but is not able to do the same for clinical trials regarding animal health?

During the early days of the AIDS epidemic, the HELPS community demanded public entry to clinical trials. In 1988,   the U. Ersus. Congress passed the Health Omnibus Programs Extension Act of 1988 (Public Law 100-607) which mandated the development of the database of AIDS Medical Trials Information Services. This particular Congressional Act motivated various other non-profit disease related groupings to demand access furthermore.

The Food plus Drug Administration Modernization Action of 1997 amended the meals, Drug and Cosmetic Action and the Public Health Program Act to require the fact that NIH create a publicly available clinical trials database. This particular eventually led to the development of the site ClinicalTrials. gov.   This particular allowed tracking of drug efficacy studies resulting from authorized Investigational New Drugs (including vaccines).

The law requires (from Wiki):

  • Federally and privately funded clinical trials;
  • The purpose of each experimental drug;
  • Subject eligibility criteria in order to participate in the clinical demo;
  • The location associated with clinical trial sites becoming utilized for a study; and
  • A point of contact with regard to patients interested in enrolling in the trial.
  • The National Library of Medicine in the National Institutes associated with Health to host the general public website/database

(BTW, one of my former clients held the federal contract to support ClinicalTrials. gov and Pubmed. I have spent time in the back rooms of the NLM and do know a fair amount about these things…. )

The searchable ClinicalTrials. gov website was made available to the public via the internet on February 29, 2k.

ClinicalTrials. gov makes searching for human scientific trials easy.   For example, a quick search reveals there are over 50 clinical studies for mRNA vaccines happening and over 200 registered.  

With animals, there is no such data source.   mRNA vaccines within the “ animal health” or even veterinary markets are hard to track until the company or maybe the USDA is ready to release home elevators that product’s development or release. The USDA and/or the NIH have no mechanism for tracking potential brand new vaccines, drugs or biologics for the animal market.

Therefore , one must rely on press releases, the occasional expert reviewed paper, conference information, USDA grant and agreement notifications, university websites and company profiles for finding of such new products. Not adequate, in my opinion, and most definitely not transparent. By federal legislation, the public should have open access to the results of this type of federally funded research.

In today’s substack, the state of mRNA “ vaccines” meant for animal “ health” can be discussed.   Citing general public sources, I will review what is known and not known about commercial liaisons and partnerships, the corporations involved, continuing research and products in a variety of states of development.  


Bayer Partners with BioNTech to Develop mRNA Vaccines, Drugs for Animal Health

Genetic Anatomist and Biotechnology News.   May 10,   2016

Bayer can partner with BioNTech to develop new, first-in-class mRNA vaccines and therapeutics for animal health indications , the companies said today, under a collaboration whose value was not disclosed.

Bayer agreed to secure exclusive rights to BioNTech’s mRNA technology and mental property for development of mRNA vaccines for animal wellness applications…

The companies said their relationship is the first of its kind focused on developing mRNA therapeutics specifically for animal health programs.

Infectious disease vaccines is the focus of one of the three therapy platforms BioNTech is building through mRNA technologies; another two are cancer immunotherapies and protein replacement. The three platforms are designed to produce pharmacologically optimized protein coding RNA for targeted  in vivo   delivery…

2016. This means that Bayer plus BioNTech have been working on animals and companion animal mRNA vaccines for over six years…

Logic predicts that they will soon have livestock and companion mRNA shot and RNA therapeutics in the marketplace.


Bayer, BioNTech developing new mRNA vaccines

Feedstuffs. com May 16, 2016

Companies collaborate on cutting-edge technology to develop new solutions to protect companion and farm animal health.

Again, note the date… 2016. Which means that Bayer and BioNTech have been working on livestock and friend animal mRNA vaccines for more than six years…

There are three therapy platforms that BioNTech has been building through mRNA technology to be used in livestock and companion animals.

  • Contagious disease vaccines
  • Cancer immunotherapies and
  • Protein replacement.

Bayer to manufacture mRNA vaccine in Indonesia

Bajuware (umgangssprachlich) Website, February 1, 2021

“ Following discussions with the German government it has become clear that current manufacturing capacities for vaccines need to be increased, particularly for potential variations of the SARS-CoV-2 virus.

This includes the need to broaden production capacity as well as related manufacturing expertise in Australia.

We in Bayer will contribute even more by making more vaccine available to help fight the outbreak.

So , Bayer lent their mRNA manufacturing vaccine facilities to be used for the making of COVID-19 mRNA vaccines. Given the above mentioned 2016 press releases, that Bajuware (umgangssprachlich) and BioNtech were collaborating to make mRNA vaccines for the animal markets, it would make sense that these facilities were in fact built for the production associated with veterinary vaccines.


SEQUIVITY: Custom Swine Vaccines, using RNA vaccines.

Merck Website, Accessed Jan 2023

Combat current and upcoming swine diseases with SEQUIVITY from Merck Animal Wellness.   revolutionary swine vaccine platform , SEQUIVITY harnesses  RNA particle technology   to create customized prescription vaccines against strains of influenza A virus in swine, porcine circovirus (PCV), rotavirus and beyond. It’s backed by a sophisticated dashboard filled up with comprehensive data and insights, all to help you stay on best.

Crucial that you know. Merck is already selling mRNA vaccines for swine. For whatever reason, they are selling these items as “ personalized prescription vaccines   against strains of influenza A virus in swine, porcine circovirus (PCV), rotavirus and beyond. ” It is really an interesting market segment. Merck’s reason to limit the production of mRNA vaccines within the “ customized prescription” market is unclear.   Production facility dimension and scaleability of the RNA product could be factors.


Purchase Expands and Complements Merck Animal Health’s Strong Shot Portfolio

Merck Press Release, November twelve, 2015 5: 00 pm ET

MADISON, N. J., Nov 12, 2015 – Merck Animal Health (known since MSD Animal Health outside the United States and Canada) plus Harrisvaccines, Inc., today introduced the companies have entered into an agreement under which Merck Pet Health will acquire Harrisvaccines, a privately-held company that develops, manufactures and markets vaccines for food production and companion animals.

“ As a innovator in biologics, Merck Animal Health has built a robust portfolio of vaccines across just about all animal species, ” mentioned Rick DeLuca, president, Merck Animal Health. “ Merging Harrisvaccines’ R& D and portfolio of products with our strong capabilities and worldwide reach will enable us to address even more devastating illnesses that are impacting production pets and reinforce our commitment towards the science of healthier creatures. ”

Harrisvaccines offers innovative technology and an   important portfolio of vaccines, using a focus on production animals , an increasingly important segment since consumer demand for proteins continues to grow worldwide.   The company has a unique RNA Particle technology which represents a breakthrough in shot development. It also has a highly versatile production platform capable to target a wide range of viruses plus bacteria. Pathogens are gathered from a farm and specific genes are sequenced and inserted into RNA particles, making safe, potent vaccines able to provide herd-specific safety.

This pioneering system is rapidly adaptable to new condition challenges and was a key component in producing the first conditionally licensed vaccine to help manage Porcine Epidemic Diarrhea Malware (PEDv), a deadly trojan that has killed more than 8 million piglets since abruptly emerging in the U. H. in 2013.

Read that last paragraph again. Gradually.

Sometime before 2015, the USDA issued a conditional license for a mRNA vaccine for use in pigs for  Porcine Epidemic Diarrhea Virus (PEDv), information regarding this product can be found at  drugs. com .

Basically something akin to an emergency use consent was issued around 2014 or 2015. Just like using the mRNA COVID-19 vaccine, full licensure was not granted however the conditional license remains in position. Is this a strategy to prevent the USDA vaccine license and/or authorization process?

To conclude:

Like with the BioNtech’s veterinary mRNA vaccine development, Merck’s development of an mRNA shot product started years ago. Meant for Merck, it may have begun in earnest in 2015 with the acquisition of Harris Vaccine.


A few ongoing research:

NOVEL MRNA VACCINE TECHNOLOGY FOR AVOIDANCE OF BOVINE RESPIRATORY SYNCYTIAL VIRUS

IOWA STATE UNIVERSITY (grant summary page)

Non Technical Summary

Bovine respiratory system syncytial virus (RSV) is a significant viral pathogens of young cows that is a key component of the respiratory disease complex and often leads to supplementary bacterial pneumonia. Prefusion Farrenheit has recently shown to be highly suitable in barrier housed RSV challenged cows. However , the difficulty in generating prefusion Farrenheit along with the cost of its manufacturing are a hurdle for adopting to the farm. RSV immunity also tends to wane rapidly and given the complications of field or pen raised cattle and their own stressors and other circulating diseases, and a protein vaccine might not prove highly efficacious in the real world. Here, we will check a novel mRNA shot system we have developed that will substantially lowers the price point for production animals and may lead to more thermal stable transcripts compatible with vaccinating for the farm. The use of an alternative delivery system rather than lipid nanoparticles will also lower the shot costs. We expect to demonstrate efficacy of the vaccine system using mice at first since proof of principle before switching to a full cow vaccination and challenge system within year 2 . Our overall goal is to test the novel mRNA system intended for inducing immunological protection from bovine RSV infection. We hypothesize that a prefusion F mRNA delivered continuously by shot implant will lead to prolonged and robust cellular and antibody immunity. Here, we will optimize our vaccine more and then test for potential correlates of protection to examine for in eventually questioned cows.


Research into mRNA shot livestock vaccines in New Zealand and Australia proceeds with governmental fast-track acceptance.

NSW fast tracks mRNA FMD and Lumpy Skin Disease vaccines (in cattle)

The NSW Federal government has taken another step in the direction of fast tracking the world very first mRNA vaccines for Foot and Mouth Disease (FMD) and Lumpy Skin Disease, tattooing a deal with US biotechnology company  Tiba Biotech

A Foot and Mouth area Disease mRNA Vaccine Deal Has Been Signed Between the NSW Government and US Corporation Tiba Biotech


Finally, asking minds want to know… what exactly is Pfizer up to?

Pfizer animal health passes the name Zoetis.

Zoetis clearly does not make its animal vaccine developing stages known to the public. Internet searches do not reveal much inside the workings of Zoetis, in terms of mRNA vaccines. Nevertheless , we can safely assume that progress mRNA vaccines and therapeutics for “ animal health” are underway – so stay tuned.


Finally, there are mRNA vaccines for COVID-19 meant for wildlife that have been developed and authorized for distribution with the USDA.

Black-footed ferret COVID-19 vaccination seems to be working

The Wildlife Community, Feb 18, 2021

After getting similar species can be infected, researchers quickly began to  increase security protocols   at zoos and the Oughout. S. Fish and Wildlife Service’s National Black-footed Dig up Conservation Center in Co, the main source of the captive-breeding and release program to get the  federally endangered   species.

“ They have done a magnificent job in keeping those animals secure, ” said Tonie Rocke, a research scientist with the USGS National Wildlife Health Center who works with ferrets.

But U. S i9000. Geological Survey researchers whom also study black-footed ferrets had learned about recent studies in mice and hamsters, demonstrating safety and efficacy of vaccination against COVID-19 using purified viral protein. They decided to try something similar on a handful of ferrets this past May and 06.

The vaccine used in ferrets is different — it’s a simplified edition of the Moderna or Pfizer vaccinations now being used for human beings   — and it’s really based on a similar protein, stated Rocke.

Beneath the authority of the USFWS, the particular scientists could test the solution on a handful of ferrets in a process that is much quicker than the extensive approvals needed for industrial vaccination for humans like the Pfizer or Moderna inoculations.

The isolated ferrets that had received this trial vaccination produced antibodies against the coronavirus.

Unfortunately, I could find no updates for this program and whether it was expanded into other animals populations.

Once again, something akin to an emergency make use of authorization was issued for this experimental vaccine. Just like using the mRNA COVID-19 vaccine and the RNA porcine vaccine over, full licensure was not granted but it appears that the conditional license remains in place. We raise the question again, are these claims a USDA and/or business strategy to circumvent the UNITED STATES DEPARTMENT OF AGRICULTURE vaccine licensing and/or authorization process?

The problem being of course , that there is simply no mechanism for “ right to know” of animal health vaccine development.


There were news stories in 2020 that mRNA vaccine(s) were being developed for COVID/SARS-CoV-2 for administration to livestock and companion animals. However , the lack of updates suggest that these plans might have been scrapped with the new, much less virulent variants.



Leave a Reply

Your email address will not be published. Required fields are marked *